李秋波 蔡文仙 孫廣斐 朱翠平
濟(jì)寧醫(yī)學(xué)院附屬醫(yī)院兒科 濟(jì)寧 272000
托吡酯及丙戊酸鈉對(duì)癲癇患兒血清六種常微量元素的影響
李秋波 蔡文仙 孫廣斐 朱翠平
濟(jì)寧醫(yī)學(xué)院附屬醫(yī)院兒科 濟(jì)寧 272000
目的 觀察托吡酯及丙戊酸鈉對(duì)癲癇患兒血清六種常微量元素的影響。方法 選取80例癲癇患兒,40例予托吡酯(TPM)單藥治療,40例予丙戊酸鈉(VPA)單藥治療,選取40例健康兒童作正常對(duì)照。所有兒童于治療前及治療6個(gè)月后行鋅、鐵、銅、鈣、鎂及鉛檢測(cè)。結(jié)果 癲癇患兒治療前血清鈣、鐵及鋅分別為(1.45±0.40)mmol/L、(7.25±2.16)mmol/L、(69.88±10.99)μmol/L,明顯低于對(duì)照組[分別為(1.66±0.45)mmol/L、(8.26±2.65)mmol/L、(78.24±12.44)μmol/L],差異有統(tǒng)計(jì)學(xué)意義(P<0.05),銅、鎂及鉛含量與對(duì)照組比較,差異無統(tǒng)計(jì)學(xué)意義(P>0.05)。VPA組與TPM組治療前銅、鋅、鎂、鈣、鐵及鉛含量比較,差異無統(tǒng)計(jì)學(xué)意義(P>0.05)。2組治療后各種元素含量比較,差異無統(tǒng)計(jì)學(xué)意義(P>0.05)。癲癇患兒治療前后各種元素含量比較,差異無統(tǒng)計(jì)學(xué)意義(P>0.05)。結(jié)論 癲癇患兒血清鋅、鈣及鐵含量降低。VPA及TPM治療對(duì)癲癇患兒血清鋅、鐵、銅、鈣、鎂、鉛含量無明顯影響。
癲癇;丙戊酸鈉;托吡酯;鎂;鋅;銅;鈣;鐵;鉛
鋅、鐵、銅、鈣、鎂及鉛與兒童疾病息息相關(guān),這些元素的異常對(duì)兒童健康成長有重要的意義。癲癇是兒童神經(jīng)系統(tǒng)常見病。有研究表明,癲癇及抗癲癇藥物對(duì)常微量元素有一定的影響[1]。本研究通過觀察癲癇患兒治療前后血清鋅、鐵、銅、鈣、鎂及鉛含量,分析常微量元素變化,以促進(jìn)癲癇患兒的健康成長。
1.1 一般資料 選擇2009-09—2011-09在濟(jì)寧醫(yī)學(xué)院附屬醫(yī)院兒科門診診治的癲癇患兒80例,均經(jīng)臨床及腦電圖確診,均為部分性發(fā)作。癲癇的診斷標(biāo)準(zhǔn)符合1989年國際抗癲癇聯(lián)盟關(guān)于癲癇發(fā)作的分類標(biāo)準(zhǔn)[2],尚未予抗癲癇藥物治療。40例予托吡酯(TPM)單藥治療,男23例,女17例;年齡3~6歲;病程3~6個(gè)月。40例予丙戊酸鈉(VPA)單藥治療,男21例,女19例;年齡3~5歲;病程4~6個(gè)月。選取40例健康兒童作正常對(duì)照,均無癲癇及其他神經(jīng)系統(tǒng)疾病,男20例,女20例;年齡3~5歲。各組性別及年齡方面差異均無統(tǒng)計(jì)學(xué)意義(P>0.05)。所有兒童未曾使用過其他影響銅、鋅、鎂、鈣、鐵、鉛代謝的藥物,所有患兒均居住于山東省濟(jì)寧市。無先天性心臟病、腭裂、活動(dòng)性肺結(jié)核史,無營養(yǎng)不良史,無惡性腫瘤史。所有患兒于治療前及治療6個(gè)月后行鋅、鐵、銅、鈣、鎂、鉛檢測(cè)?;純簷z測(cè)時(shí)24 h以上無癲癇發(fā)作。
1.2 方法 采血前用醫(yī)用酒精進(jìn)行皮膚消毒,用消毒的無鉛干棉球吸干皮膚表面的酒精。用一次性定量取血管吸取規(guī)定量指尖血(銅、鋅、鎂、鈣及鐵為20 μL,鉛為20 μL)。用北京博暉創(chuàng)新光電技術(shù)股份有限公司生產(chǎn)的BH5100S、BH2100T原子吸收光譜儀檢測(cè)全血銅、鋅、鎂、鈣、鐵及鉛元素的含量。
癲癇患兒治療前鋅、鈣及鐵含量低于對(duì)照組,差異有統(tǒng)計(jì)學(xué)意義(鐵P<0.05,鈣和鋅P<0.01)。銅、鎂及鉛含量與對(duì)照組比較,差異無統(tǒng)計(jì)學(xué)意義(P>0.05)。2組癲癇患兒治療前銅、鋅、鎂、鈣、鐵及鉛含量比較,差異無統(tǒng)計(jì)學(xué)意義(P>0.05)。癲癇患兒治療前后各種元素含量比較,差異無統(tǒng)計(jì)學(xué)意義(P>0.05)。2組患兒治療后各種元素含量比較,差異亦無統(tǒng)計(jì)學(xué)意義(P>0.05)。見表1。
表1 各組鋅、鐵、銅、鈣、鎂、鉛變化
注:與對(duì)照組比較,#P<0.05,*P<0.01
兒童處于智力和體格發(fā)育的關(guān)鍵階段,各種營養(yǎng)素需求量較多[3],鐵、鎂、鋅、銅、鈣及鉛對(duì)于機(jī)體生長發(fā)育有重要意義。各種原因可導(dǎo)致體內(nèi)這些元素的吸收、代謝異常,引起上述元素的缺乏或過量,導(dǎo)致機(jī)體代謝障礙[4]。
人體中的鈣主要分布在骨骼和牙齒中,只有極少數(shù)的鈣被溶解到血液中。癲癇發(fā)作使神經(jīng)元細(xì)胞處于興奮狀態(tài),生成大量的自由基,線粒體膜受損傷,通透性增加,引起線粒體鈣釋放及血清鈣含量升高。神經(jīng)元鈣超載在癲癇腦損傷中起著重要作用,Ca2+作為信使參與多種細(xì)胞功能活動(dòng)的調(diào)節(jié),神經(jīng)元細(xì)胞鈣超載是導(dǎo)致癲癇腦損傷的直接原因[5]。鈣拮抗劑或鈣通道阻斷劑治療癲癇患者有較好的治療效果。腦組織中鎂含量可影響神經(jīng)細(xì)胞生理、生化平衡。鎂是細(xì)胞代謝許多酶的激活劑,特別是有關(guān)ATP代謝的酶,起到影響腦細(xì)胞能量代謝的作用。Mg2+是N-甲基-D-天冬氨酸受體的非競爭性拮抗劑和谷氨酸釋放抑制劑。Mg2+是鈣拮抗劑,可阻斷神經(jīng)細(xì)胞膜電壓調(diào)節(jié)鈣通道和受體閘門通道,抑制鈣內(nèi)流[6],影響神經(jīng)細(xì)胞功能。鋅是腦發(fā)育中不可缺少的元素,參與脫氧核糖核酸、核糖核酸、蛋白質(zhì)的合成,從復(fù)制和轉(zhuǎn)錄水平影響含鋅神經(jīng)遞質(zhì)的合成,有降低中樞神經(jīng)系統(tǒng)興奮性的作用[7]。銅是腦內(nèi)Na+-K+-ATP酶抑制劑,可影響能量供應(yīng),破壞細(xì)胞膜離子梯度,引起細(xì)胞膜不穩(wěn)定[8],可能與癲癇發(fā)作有關(guān)。研究顯示,向動(dòng)物腦組織內(nèi)注射銅,可使動(dòng)物產(chǎn)生驚厥癥狀。鐵是人體含量最豐富且對(duì)中樞神經(jīng)系統(tǒng)正常功能影響較大的微量元素,參與神經(jīng)遞質(zhì)的代謝,若體內(nèi)鐵含量降低,可導(dǎo)致單胺類神經(jīng)遞質(zhì)活性受到影響,損害中樞神經(jīng)系統(tǒng)發(fā)育[9]。鉛在環(huán)境中普遍存在,有神經(jīng)毒性,鉛通過抑制血漿超氧化物歧化酶活性,降低自由基清除率,損傷腦內(nèi)星狀細(xì)胞,引起中樞神經(jīng)系統(tǒng)損害[10]。
癲癇是兒童期常見神經(jīng)系統(tǒng)疾病,部分患兒預(yù)后差,存在嚴(yán)重智力運(yùn)動(dòng)發(fā)育障礙[11]。TPM及VPA是常見的抗癲癇藥物,對(duì)于多種類型癲癇均有良好的效果,改善癥狀,提高患兒生命質(zhì)量,但也可出現(xiàn)皮疹、肝功損害、影響骨代謝、影響食欲等不良反應(yīng)[12]。TPM治療后部分患兒出現(xiàn)食欲減退,而VPA治療后部分患兒出現(xiàn)食欲增加。有研究表明,癲癇患兒體內(nèi)微量元素及常量元素含量異常[13-14]。本研究中癲癇患兒治療前血清鋅、鈣及鐵含量低于對(duì)照組,差異有統(tǒng)計(jì)學(xué)意義。目前,抗癲癇藥物對(duì)于微量元素及常量元素的影響仍存在爭議。Sarangi等[15]研究提示,抗癲癇藥物對(duì)多種元素有影響。而Ilhan等[16]研究提示,抗癲癇藥物對(duì)鎂、鋅、銅及錳無影響。本研究中癲癇患兒治療前后各種元素含量比較,差異無統(tǒng)計(jì)學(xué)意義。
鐵、鎂、鋅、銅、鈣及鉛在體內(nèi)不能合成,只能來自外源性物質(zhì),其含量異??蓪?dǎo)致正常生理功能的紊亂,引起各種各樣的疾病,癲癇患兒存在鋅、鈣及鐵含量異常,其發(fā)病機(jī)制及對(duì)癲癇患兒有何種影響,目前尚不清楚,需進(jìn)一步研究。
[1] Gonullu H,Gonullu E,Karadas S,et al.The levels of trace elements and heavy metals in patients with acute migraine headache[J].J Pak Med Assoc,2015,65(7):694-697.
[2] 吳遜,李文慧.國際抗癲癇聯(lián)盟和名詞委員會(huì)推薦的癲癇發(fā)作的臨床及腦電圖分類[J].中華神經(jīng)科雜志,2001,34(3):187-189.
[3] 王軍文,陳衛(wèi),吳娜娜,等.四川江油地區(qū)兒童全血微量元素缺乏調(diào)查分析[J].國際檢驗(yàn)醫(yī)學(xué)雜志,2015, 36(22):3 354-3 355.
[4] Karadas S,Sayn R,Aslan M,et al.Serum levels of trace elements and heavy metals in patients with acute hemorrhagic stroke[J].J Membr Biol,2014,247(2):175-180.
[5] Steinlein OK.Calcium signaling and epilepsy[J].Cell Tissue Res,2014,357(2):385-393.
[6] Adebamowo SN,Spiegelman D,Willett WC,et al.Association between intakes of magnesium,potassium,and calcium and risk of stroke:2 cohorts of US women and updated meta-analyses[J].Am J Clin Nutr,2015, 101(6):1 269-1 277.
[7] Pan K,Yi CW,Chen J,et al.Zinc significantly changes the aggregation pathway and the conformation of aggregates of human prion protein[J].Biochim Biophys Acta,2015,1 854(8):907-918.
[8] Zhang JW,Liu JX,Hou HM,et al.Effects of tetrathiomolybdate and penicillamine on brain hydroxyl radical and free copper levels:a microdialysis study in vivo[J].Biochem Biophys Res Commun,2015,458(1):82-85.
[9] Strahle JM,Garton T,Bazzi AA,et al.Role of hemog-lobin and iron in hydrocephalus after neonatal intraventricular hemorrhage[J].Neurosurgery,2014,75(6):696-705.
[10] Eum KD,Seals RM,Taylor KM,et al.Modification of the association between lead exposure and amyotrophic lateral sclerosis by iron and oxidative stress related gene polymorphisms[J].Amyotroph Lateral Scler Frontotemporal Degener,2015,16(1/2):72-79.
[11] 楊志仙,張?jiān)氯A.癲癇性腦病研究進(jìn)展[J].中華實(shí)用兒科臨床雜志,2015,30(12):954-958.
[12] 陳鳳民,邢燕,任純明.拉莫三嗪聯(lián)合丙戊酸鈉治療小兒癲癇臨床觀察[J].中華實(shí)用診斷與治療雜志,2014,28(8):828-829.
[13] Prasad DK,Shaheen U,Satyanarayana U,et al.Association of serum trace elements and minerals with genetic generalized epilepsy and idiopathic intractable epilepsy[J].Neurochem Res,2014,39(12):2 370-2 376.
[14] Saad K,Hammad E,Hassan AF,et al.Trace element,oxidant,and antioxidant enzyme values in blood of children with refractory epilepsy[J].Int J Neurosci,2014,124(3):181-186.
[15] Sarangi SC,Tripathi M,Kakkar AK,et al.Effect of antiepileptic therapy on trace elements status in Indian population in a tertiary care hospital from northern India:a cross sectional study[J].Epilepsy Res,2014, 108(5):917-927.
[16] Ilhan A,Uz E,Kali S,et al.Serum and hair trace element levels in patients with epilepsy and healthy subjects:does the antiepileptic therapy affect the element concentrations of hair[J].Eur J Neurol,1999,6(6):705-709.
(收稿2016-12-04)
Effects of topiramate and sodium valproate on six constant/trace elements in serum of children with epilepsy
Li Qiubo,Cai Wenxian,Sun Guangfei,Zhu Cuiping
Department of Pediatrics,Affiliated Hospital of Jining Medical College,Jining 272000,China
Objective To investigate effects of topiramate and sodium valproate on six constant/trace elements in serum of children with epilepsy.Methods Eighty children with epilepsy participated in the study.40 cases were treated with TPM monotherapy,and 40 cases were treated with VPA monotherapy.40 healthy children were selected as normal control.Magnesium,zinc,copper,calcium,iron and lead levels were assayed before and after six months of treatment.Results Children with epilepsy had significant low levels of calcium,iron and zinc(1.45±0.40)mmol/L,(7.25±2.16)mmol/L and(69.88±10.99)μmol/L,respectively,and the corresponding values for controls were(1.66±0.45)mmol/L,(8.26±2.65)mmol/L and(78.24±12.44)μmol/L,respectively.Compared with the control group,there was no significant difference in the content of copper,magnesium and lead in children with epilepsy.There were no significant differences in the content of copper,zinc,magnesium,calcium,iron and lead between the VPA group and the TPM group before treatment.There was no significant difference in the contents of various elements in the two groups after treatment.There was no significant difference in the content of various elements in children with epilepsy before and after treatment.Conclusion Serum zinc,calcium and iron levels are significantly decreased in children with epilepsy.VPA and TPM treatment have no significant effect on serum magnesium,zinc,copper,calcium,iron and lead content in children with epilepsy.
Epilepsy;Sodium valproate;Topiramate;Magnesium;Zinc;Copper;Calcium;Iron;Lead
R742.1
A
1673-5110(2017)11-0041-03